Pharmaceutical CDMO Recipharm announced on Monday that its subsidiary ReciBioPharm has secured a three-year grant from the Bill & Melinda Gates Foundation to support the global deployment of its xRNA Continuous Manufacturing platform.
The funding will focus on enhancing inline Process Analytical Technologies (PAT) and predictive analytics software for Low- and Middle-Income Countries (LMICs). This initiative aims to improve the scalability, quality and accessibility of RNA-based therapeutics.
ReciBioPharm's platform is designed to advance the development of fully integrated, continuous processes within biomanufacturing. The project builds on innovations from an MIT initiative funded by the FDA. ReciBioPharm is committed to leveraging these technologies to address global health challenges. This grant reinforces the company's role in expanding access to critical RNA solutions worldwide.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval